Navigation Links
Plant pathogen yields substance to fight neuroblastoma
Date:1/17/2008

Drug treatment of neuroblastoma, a tumor of the nervous system in children, poses major problems. Therefore, scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have been searching for substances that are suitable as a basis for developing better drugs. Now they have found a candidate: HC-toxin, which is isolated from a fungal plant pathogen. The substance from the maize pathogen reprograms neuroblastoma cells in such a way that they behave almost like healthy cells again.

Normally, the fungus Helminthosporium carbonum leads to reduced harvests for maize farmers. Yet a specific constituent of the pathogen, namely HC-toxin, might be very useful for medicine. The substance is used by scientists as a basis for developing a new anti-cancer drug. HC-toxin acts on enzymes known as histone deacetylases (HDACs), which structure the packaging of the genetic material, or DNA. HDAC enzymes change, among others, the histones proteins around which the DNA is wrapped. Alterations in the packaging of the genetic material are suspected to cause cancer or promote its spread. Therefore, scientists are studying substances that inhibit HDAC enzymes for their ability to fight malignant tumors.

Among these substances is HC-toxin, which has now been investigated by researchers of the Clinical Cooperation Unit Pediatric Oncology at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ). They found out that neuroblastoma cells lose several of their cancer-typical properties when under the influence of the substance: They divide less frequently, show less invasive growth and even their outside appearance resembles healthy nerve cells again. These effects were observed to be stronger than with other HDAC inhibitors investigated previously.

The effect of HC-toxin is presumably based, among other things, on the fact that it promotes the function of an important cellular cancer brake known as RB signaling pathway. The investigators found out that the cancer brake was much more active in tumors cells that had been treated with HC-toxin than in untreated cells. They plan to conduct further research to determine whether the substance derived from the maize pathogen is suitable for developing a new drug to fight neuroblastoma.

Neuroblastoma is the second most frequent malignant tumor in children. With an average of 150 new cases diagnosed in Germany each year, neuroblastoma constitutes about seven to eight percent of all childhood cancers. Most affected children are in preschool age, one third are diagnosed under one year of age. Although treatment has been improved over the past few years, chances of recovery from advanced stage neuroblastoma continue to be very low. In addition, the drugs being used often cause serious side effects.


'/>"/>

Contact: Dr. Sibylle Kohlstdt
s.kohlstaedt@dkfz.d
49-622-142-2843
Helmholtz Association of German Research Centres
Source:Eurekalert

Related medicine news :

1. Preclinical study suggests organ-transplant drug may aid in lupus fight
2. Study provides hope that some transplant patients could live free of antirejection drugs
3. Study provides hope that some transplant patients could live free of anti-rejection drugs
4. Advanced Age No Bar to Liver Transplant
5. Nanowire coating for bone implants, stents
6. Circulating fats kill transplanted pancreas cells, study shows
7. Latest DES Analysis Stresses Importance of Physicians Well-Trained in Implantation Technique and Patient Follow-Up
8. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
9. Implantable device designed to detect, stop seizures under study at MCG
10. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
11. Bone-growing nanomaterial could improve orthopaedic implants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... , ... DDi , a Makro company, makes it ... expertise in eClinical Solutions. DDi has built its solution competency with a unique ... clients. DDi provides smarter technology for Clinical Development, Regulatory and Enterprise domains by ...
(Date:2/12/2016)... ... , ... Mystic Buddha Publishing House presents Valentine’s Day tips on different forms ... - Dr. Frederick Lenz. , According to Publisher Roger Cantu, “Blue Skies ... teaching and helping others. Valentine’s Day celebrates love in all its forms, and ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop the advanced skills needed to ... students from U.S. universities who will draw from Siemens’ deep knowledge of ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... CDRH Enforcement Trends: , Back to the ... , As Winston Churchill said, “Those who don’t learn from history are ... what to expect when they come knocking this year. But that takes time. , ...
(Date:2/12/2016)... Middletown, PA (PRWEB) , ... February 12, 2016 , ... ... year’s event will be held in Anaheim, CA at the Anaheim Convention Center. Almost ... they can see new therapy products in action, learn more about their chosen field ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Feb. 11, 2016 The primary goal of ... adoption patterns on the usage of liquid biopsy. Key ... - Timeframe of liquid biopsy adoption amidst ... and Evs—by organization type - Sample inflow to conduct ... saliva, stool, serum, and so on. - Correlation analysis ...
(Date:2/11/2016)... Calif. , Feb. 11, 2016  Walgreens has ... across 39 states and Washington, D.C. ... a move that was commended by shareholder advocacy organization As ... at As You Sow. "Many people hold on to unneeded ... which can have tragic consequences." --> Conrad ...
(Date:2/11/2016)...  MiMedx Group, Inc. (NASDAQ: MDXG ), the ... other birth tissues, human skin and bone, and patent-protected ... products and therapies, announced today that it will present ... in New York , NY.  Parker ... Senken , Chief Financial Officer and Chris Cashman ...
Breaking Medicine Technology: